Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours (colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)

Next Previous
Search
Trial Profile

An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours (colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OATD-02 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Molecure

    • Most Recent Events

    • 24 Feb 2025 Planned End Date changed from 1 Nov 2024 to 1 Dec 2025.
    • 24 Feb 2025 Planned primary completion date changed from 1 Nov 2024 to 1 Dec 2025.
    • 03 Apr 2024 According to a Molecure media release, the company is planning to dose fourth cohort imminently and has successful completion of a public offering which will be use to fund completion of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top